Suggestions
Morten Henneveld
CEO I Board member I Advisor I P&L I Transformation & Growth I Strategy I Commercial Excellence I M&A & PMI
Morten Henneveld is a prominent figure in the medical technology sector, currently serving as a member of the Board of Directors at SIME Diagnostics. He is also the CEO of OssDsign, a company specializing in innovative solutions for orthopedic and cranial applications.
Professional Background
- Current Role: Morten leads OssDsign, where he has been instrumental in driving the company's growth and market presence. Under his leadership, OssDsign has achieved significant milestones, including completing over 5,000 patient cases in the U.S. .12
- Expertise: He possesses extensive experience in business transformation, sales strategies, and presenting to boards, showcasing his versatility in both operational and strategic roles .14
Contributions and Achievements
- Morten has been actively involved in various initiatives aimed at enhancing patient care through innovative products. His leadership has helped position OssDsign as a key player in the orthobiologics market .35
- He frequently engages with stakeholders, including sales teams and customers, to foster collaboration and drive business success .67
Overall, Morten Henneveld's contributions to the medical technology field reflect his commitment to advancing healthcare solutions and improving patient outcomes.
Highlights
Yesterday I met with Sten Gustafsson at ABG Sundal Collier to talk about the performance in OssDsign (now as a new young orthobiologics company), the state of the US spine market as well as the future opportunity we have created for ourselves.
Specifically, we talked about the growth drivers for the future, where we see four clear areas:
- Broader access and coverage in the U.S. market
- Product portfolio expansion
- Build further real-world clinical evidence
- Enter new orthopedic segments
In sum, the company but has come a long way in a very short amount of time and we look forward to continuing the journey through laser-focused execution of the above areas.
https://lnkd.in/eNsQ2QWy
Yesterday we released our Q2 result marking the 9th consecutive quarter with triple-digit growth in the US, reaching SEK 100m in orthobiologics sales on a 12 months rolling basis - only two years after recording first meaningful sales.
Our gross margin also continued to develop favorably, coming in at 93.2%, up 18.6% year over year. I'm very pleased to see the gross margin now being stable well above 90% for the last two quarters.
Q2 also saw a number of important developments in the company:
We won two important contracts - one with Premier, one of the giant GPOs, and the second with the VA, which means we now have universal access to all US military personnel, active and veterans.
We also saw the first peer-reviewed clinical publications from our spine registry, PROPEL, with both cases showing now only great outcomes but also fast fusion. These results are in line with our pre-clinical results as well as our TOP FUSION study.
And last, but certainly not least, we reached another milestone as we exceeded 5,000 patients treated with OssDsign Catalyst. An achievement everyone in OssDsign is immensely proud of.
Go OssDsign team!
